This Marijuana Stock Could Be 1 Clinical Trial Away From a $1 Billion Valuation
Few industries in the U.S. are growing at a quicker pace than legal marijuana. According to a fairly recent report from Marijuana Business Daily, entitled "Marijuana Business Factbook 2017," legal pot sales in the U.S. are expected to rise by about 30% in 2017 to a range of $5.1 billion to $6.1 billion, with the total U.S. market expected to expand to around $17 billion by 2021.
The public's perception of cannabis has also seen a pretty discernable shift since the mid-1990s. Gallup, which has been conducting surveys on the public's opinion of marijuana since the late 1960s, found just 25% support for a national legalization effort in 1995. As of 2016, support for legalizing the drug was up to 60%, which represents an all-time high since Gallup began its polling.
Image source: Getty Images.
Source: Fool.com
Cara Therapeutics Inc. Stock
Our community is currently high on Cara Therapeutics Inc. with 10 Buy predictions and 7 Sell predictions.
Based on the current price of 0.32 € the target price of 4 € shows a potential of 1139.93% for Cara Therapeutics Inc. which would more than double the current price.
